COMP <GO>
PVLA vs LKFT // EV/EBITDA & P/E VALUATION
Palvella Therapeutics Inc. (NASDAQ) VS. Lakefront Biotherapeutics (NASDAQ) • 15-METRIC TALLY: PVLA 1
— LKFT 1
■ METRIC PARITY
LAST: $151.58 (+2.79%) • MKT CAP: $2.18B
valuation
—
LAST: $32.33 (+0.78%) • MKT CAP: $2.13B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PVLA VS. LKFT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PVLA | LKFT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.90% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.14% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.5 | 69.8 | -10.23 | LKFT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.18B | $2.13B | $53.6M | PVLA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PVLA REV | LKFT REV | PVLA GROSS % | LKFT GROSS % | PVLA FCF | LKFT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$25.0M | — |
| FY 2024 | $0 | — | — | — | -$10.8M | — |
| FY 2023 | $42.8M | — | — | — | -$13.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PVLA // BETA —
LKFT // BETA —